Neucruit has been helping rapid lateral flow testing for COVID-19
This client is an innovative health company making medicine more proactive
Finding sufficient patients that were in the specific 2-5 day window of COVID infection
Neucruit provided the patient recruitment solution, utilising social media to outreach to potential patients
Neucruit recruited all 30 patients with viral COVID-19 (in days 2-5 of symptoms) in 28 days, reducing timelines by 93%
About the client
Our client is a predictive health company focused on making medicine more proactive. They are an innovative UK, and VC backed start-up supported by one of the UK’s top universities.
‘A team of scientists, engineers, and designers solving the world’s most critical healthcare problems.’
" Neucruit facilitated a 93% reduction in outreach timelines"
Using Neucruit to accelerate research
The clients’ team approached Neucruit after struggling to recruit sufficient participants to test their novel lateral flow test.
Finding these patients and efficiently processing them within their infective period was difficult, also the study organisers had recruited only 5 patients in 48 days. This significantly delayed the validation of their lateral flow tests.
Nevertheless, Neucruit successfully recruited all 30 patients with viral COVID-19 (in days 2-5 of symptoms) within 28 days, reducing timelines by 93%.
Neucruit is a global platform that uses real-time data to help biopharmaceutical companies, site teams, and investigators enhance clinical research planning and delivery through intelligent analytics on the patient journey. Furthermore, Neucruit combines unique patient insights with longitudinal clinical data to optimise site selection patient recruitment and gain insights that can’t be easily accessed through traditional methods. If you want to know more about us and our work, please contact us.